Release Date: Jul 2017
MOC: PC, MK, SBP
Christopher Doern, PhD
Associate Director of Clinical Microbiology, VCU Health System; Assistant Professor of Pathology, VCU School of Medicine, Richmond, VA
This course will discuss the clinical utility and laboratory testing of several newly introduced antimicrobials including isavuconazole, ceftazidime/avibactam, ceftolozane/tazobactam, as well as dalbavancin/oritivancin. The session will describe the clinical situations in which these drugs will be useful and will review the pertinent literature relevant to their activity against the pertinent organisms. Lastly, a detailed discussion of the laboratory considerations for providing antimicrobial susceptibility testing for each one of these drugs will be provided.
After attending this session, participants will be able to:
· Identify new antibacterial agents and their utility for the treatment of multi-drug resistant infections.
· Identify new antifungal agents and their utility for the treatment of invasive fungal infections.
· Describe the laboratory testing considerations for new antimicrobials discussed.
Who should attend? Practicing Pathologists, Residents, Bench Supervisors, Bench Technologists & Technicians